Photocure ASA
PHCUF
Other OTC6.01
USD
- -
- -
ISIN
NO0010000045
Return %
Stock
S&P500
1Y
0.17
19.01
3Y
26.53
65.48
5Y
-65.78
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Daniel Schneider
- Full Time Employees
- 99
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Hoffsveien 4 Oslo PS Norway 0275
- IPO Date
- Sep 24, 2013
- Website
- photocure.com
- Similar Companies
- Business
- Photocure ASA, a Norwegian specialty pharmaceutical company founded in 1993 and headquartered in Oslo, develops, produces, markets and sells photodynamic technology-based pharmaceuticals and medical devices focused on bladder cancer diagnostics and management. The company commercializes Hexvix (in Europe) and Cysview (in North America), hexyl aminolevulinate hydrochloride pharmaceuticals used as adjuncts to white light cystoscopy in blue light cystoscopy (BLC) systems from third-party manufacturers including Karl Storz, Richard Wolf and Olympus, enabling cancer cells to glow pink for improved detection, resection and surveillance in non-muscle invasive bladder cancer (NMIBC) patients; it also derives milestone payments, royalties and manufacturing revenue from out-licensed programs such as Cevira for cervical high-grade squamous intraepithelial lesions (HSIL) and Hexvix in China/Taiwan to partner Asieris. Photocure operates directly in the U.S. and Europe with approximately 100 employees across commercial (35 in North America, 27 in Europe) and development segments, generating primary revenues from its Hexvix/Cysview franchise (NOK 525 million or USD 47 million in 2024) at high gross margins of about 94 percent, while pursuing worldwide partnerships in roughly 30 countries including Endotherapeutics in Australia/New Zealand, Genotests in Chile and recent distribution expansions. In recent developments, Photocure installed 14 new Saphira BLC towers and supported ForTec's deployment of six additional mobile towers in the U.S. during Q3 2025, reaching 373 active accounts (up 23 percent quarter-over-quarter); entered a strategic partnership with Intelligent Scopes Corporation (ISC) in October 2025 to develop FDA-clearable AI software for real-time BLC enhancement with exclusive commercialization rights; advanced 49 Olympus Visera Elite III BLC systems across Europe since Q1 2025 launch; achieved early Chinese market authorization for partner Hexvix in November 2024 with commercialization underway; and anticipates Cevira NDA approval milestones in China plus U.S./EU regulatory progress, alongside efforts for FDA BLC reclassification, flexible BLC reintroduction with Richard Wolf and CMS reimbursement gains.
Photocure ASA (PHCUF) M&A Call Transcript
Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics
Photocure ASA (PHCUF) Q1 2026 Earnings Call Transcript
Photocure ASA: Results for the first quarter of 2026
Photocure ASA: Update on Regulatory Classification for OAY Equipment
Photocure ASA (PHCUF) Q4 2025 Earnings Call Transcript
Photocure ASA: Results for the fourth quarter of 2025
Photocure ASA (PHCUF) Q3 2025 Earnings Call Transcript
Photocure ASA: Results for the third quarter of 2025
Photocure ASA: Results for the second quarter of 2025
Photocure ASA: Results for the first quarter of 2025
Photocure ASA: Results for the fourth quarter of 2024
Photocure ASA: Results for the third quarter of 2024